Trong Kim Le

2.7k total citations · 1 hit paper
43 papers, 2.0k citations indexed

About

Trong Kim Le is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Pharmacology. According to data from OpenAlex, Trong Kim Le has authored 43 papers receiving a total of 2.0k indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Oncology, 12 papers in Pulmonary and Respiratory Medicine and 8 papers in Pharmacology. Recurrent topics in Trong Kim Le's work include Cancer Immunotherapy and Biomarkers (7 papers), Pain Mechanisms and Treatments (6 papers) and Musculoskeletal pain and rehabilitation (5 papers). Trong Kim Le is often cited by papers focused on Cancer Immunotherapy and Biomarkers (7 papers), Pain Mechanisms and Treatments (6 papers) and Musculoskeletal pain and rehabilitation (5 papers). Trong Kim Le collaborates with scholars based in United States, United Kingdom and France. Trong Kim Le's co-authors include Robert H. Dworkin, Joseph A. Johnston, Catherine B. Johannes, Xiaolei Zhou, Russel Burge, John L. Mershon, Deirdre Mladsi, Amy S. Chappell, Amy Barrett and R.L. Robinson and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Trong Kim Le

41 papers receiving 1.9k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The Prevalence of Chronic Pain in United States Adults: Results of an Internet-Based Survey

2010 955 citations Catherine B. Johannes, Trong Kim Le et al. Journal of Pain profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Trong Kim Le United States	13	813	606	335	291	290	43	2.0k
Nalini Sehgal United States	21	827 1.0×	506 0.8×	430 1.3×	107 0.4×	349 1.2×	41	1.8k
Bruce Parsons United States	27	631 0.8×	1.2k 2.0×	362 1.1×	142 0.5×	363 1.3×	88	2.5k
Mugdha Gore United States	18	1.1k 1.4×	986 1.6×	169 0.5×	102 0.4×	339 1.2×	29	2.2k
Rafael Gálvez Spain	21	613 0.8×	840 1.4×	241 0.7×	75 0.3×	518 1.8×	67	1.6k
Alaa Abd‐Elsayed United States	29	756 0.9×	730 1.2×	823 2.5×	126 0.4×	824 2.8×	289	2.9k
Martin Mücke Germany	20	530 0.7×	347 0.6×	129 0.4×	144 0.5×	113 0.4×	82	1.7k
Hilary Wilson United States	23	703 0.9×	430 0.7×	240 0.7×	84 0.3×	259 0.9×	66	1.8k
Mick Serpell United Kingdom	23	793 1.0×	626 1.0×	986 2.9×	134 0.5×	399 1.4×	60	2.3k
Sharon Hertz United States	15	887 1.1×	388 0.6×	281 0.8×	73 0.3×	418 1.4×	23	2.2k
Penney Cowan United States	11	936 1.2×	365 0.6×	236 0.7×	60 0.2×	359 1.2×	24	1.7k

Countries citing papers authored by Trong Kim Le

Since Specialization

Citations

This map shows the geographic impact of Trong Kim Le's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Trong Kim Le with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Trong Kim Le more than expected).

Fields of papers citing papers by Trong Kim Le

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Trong Kim Le. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Trong Kim Le. The network helps show where Trong Kim Le may publish in the future.

Co-authorship network of co-authors of Trong Kim Le

This figure shows the co-authorship network connecting the top 25 collaborators of Trong Kim Le. A scholar is included among the top collaborators of Trong Kim Le based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Trong Kim Le. Trong Kim Le is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Gu, Tao, et al.. (2024). Treatment Patterns and Costs Among US Patients With Diffuse Large B-Cell Lymphoma not Treated With 2L Stem Cell Transplantation. Future Oncology. 20(10). 623–634. 1 indexed citations

Kirkwood, John M., Lisa A. Kottschade, Robert R. McWilliams, et al.. (2023). Real-World Outcomes with Immuno-Oncology Therapies in Advanced Melanoma: Final Results of the OPTIMIzE Registry Study. Immunotherapy. 16(1). 29–42. 3 indexed citations

Le, Trong Kim, et al.. (2023). Neoadjuvant treatment and survival outcomes by pathologic complete response in HER2-negative early breast cancers. Future Oncology. 19(3). 229–244. 1 indexed citations

Nguyen, Truc, et al.. (2023). Comprehensive System for Facilitating Professional Growth by Linking Mentees and Mentors in Information Technology. 1–6. 1 indexed citations

Fisher, Maxine D., et al.. (2023). Real-World Outcomes in Metastatic HR+/HER2-, HER2+ and Triple Negative Breast Cancer after Start of First-Line Therapy. Future Oncology. 19(13). 909–923. 3 indexed citations

Zhang, Yan, et al.. (2022). Adverse Events and Clinical Outcomes in Patients Treated with PD-(L)1 Blockade for Advanced Non-Small-Cell Lung Cancer. Future Oncology. 18(40). 4509–4523. 1 indexed citations

Awan, Farrukh T., et al.. (2022). Real-World Treatment (Tx) Patterns and Clinical Outcomes Among Patients (Pts) with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Who Received at Least 2 Prior Lines of Therapy Including Bruton Tyrosine Kinase Inhibitor (BTKi) and/or B-Cell Lymphoma 2 Inhibitor (BCL2i). Blood. 140(Supplement 1). 7028–7029. 1 indexed citations

Le, Trong Kim, et al.. (2022). Abstract P3-12-15: Clinical characteristics, treatment patterns, and survival outcomes in women with early triple-negative (TN) or hormone receptor-positive/human epidermal growth factor receptor-2 negative (HR+/HER2−) breast cancer (BC) in the real-world (RW) setting. Cancer Research. 82(4_Supplement). P3–12. 1 indexed citations

Stenehjem, David D., Solomon J. Lubinga, Komal Gupte-Singh, et al.. (2020). Real-World Effectiveness of Nivolumab Monotherapy After Prior Systemic Therapy in Advanced Non–Small-Cell Lung Cancer in the United States. Clinical Lung Cancer. 22(1). e35–e47. 5 indexed citations

10.

Jabbour, Elias, et al.. (2018). Prevalence of Comorbidities Relevant to the Choice of Second-Generation (2-G) Tyrosine Kinase Inhibitor (TKI) for the Treatment of Chronic Myeloid Leukemia (CML) in the United States Using Real-World Claims Databases. Blood. 132(Supplement 1). 4265–4265. 2 indexed citations

11.

Broglio, Kristine, Melanie Quintana, Eric S. Daar, et al.. (2014). Determining Comparative Effectiveness Benchmarks for Emerging Treatments for Hepatitis C Virus (Hcv) Infection in the Single Arm Study Design Setting. Value in Health. 17(3). A2–A2. 2 indexed citations

12.

Johannes, Catherine B., Trong Kim Le, Xiaolei Zhou, Joseph A. Johnston, & Robert H. Dworkin. (2010). The Prevalence of Chronic Pain in United States Adults: Results of an Internet-Based Survey. Journal of Pain. 11(11). 1230–1239. 955 indexed citations breakdown →

13.

Roskell, Neil, S Beard, Yang Zhao, & Trong Kim Le. (2010). A Meta‐Analysis of Pain Response in the Treatment of Fibromyalgia. Pain Practice. 11(6). 516–527. 35 indexed citations

14.

Quilici, Sibilia, J Chancellor, Mickael Löthgren, et al.. (2009). Meta-analysis of duloxetine vs. pregabalin and gabapentin in the treatment of diabetic peripheral neuropathic pain. BMC Neurology. 9(1). 6–6. 155 indexed citations

15.

Zhao, Yang, Wenyu Ye, Trong Kim Le, et al.. (2009). Comparing clinical and economic characteristics between commercially-insured patients with diabetic neuropathy and demographically-matched diabetic controls. Current Medical Research and Opinion. 25(3). 585–597. 8 indexed citations

16.

Barrett, Amy, et al.. (2007). Epidemiology, Public Health Burden, and Treatment of Diabetic Peripheral Neuropathic Pain: A Review. Pain Medicine. 8(suppl 2). S50–S62. 179 indexed citations

17.

Armstrong, David G., Amy S. Chappell, Trong Kim Le, et al.. (2007). Duloxetine for the Management of Diabetic Peripheral Neuropathic Pain: Evaluation of Functional Outcomes. Pain Medicine. 8(5). 410–418. 27 indexed citations

18.

Beard, S, et al.. (2007). Cost effectiveness of duloxetine in the treatment of diabetic peripheral neuropathic pain in the UK. Current Medical Research and Opinion. 24(2). 385–399. 22 indexed citations

19.

Wernicke, Joachim, Joel Raskin, A. Rosen, et al.. (2006). Duloxetine in the long-term management of diabetic peripheral neuropathic pain: An open-label, 52-week extension of a randomized controlled clinical trial. Current Therapeutic Research. 67(5). 283–304. 21 indexed citations

20.

Le, Trong Kim, Stephen L. Able, & Maureen J. Lage. (2006). Resource use among patients with diabetes, diabetic neuropathy, or diabetes with depression. Cost Effectiveness and Resource Allocation. 4(1). 18–18. 40 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact